Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors KJ Hamblett, SD Barnscher, RH Davies, PW Hammond, A Hernandez, GR Wickman, VK Fung, T Ding, G Garnett, AS Galey, P Zwierzchowski, BC Clavette, GC Winters, JR Rich, GJ Rowse, JS Babcook and D Hausman
Title ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers
Journal
Vol
Issue
Date
URL https://cancerres.aacrjournals.org/content/79/4_Supplement/P6-17-13
Abstract Text Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-13

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
ZW49 ZW-49|ADC ZW49 HER2 (ERBB2) Antibody 47 ZW49 is an antibody-drug conjugate comprising a bispecific ERBB2 (HER2) antibody linked to an auristatin, which delivers the cytotoxic agent to ERBB2 (HER2)-expressing cells, potentially resulting in cell growth inhibition and tumor regression (Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-13).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 positive breast cancer sensitive ZW49 Preclinical - Pdx Actionable In a preclinical study, ZW49 treatment induced tumor regression in patient-derived xenograft (PDX) models of breast cancer expressing low and high levels of ERBB2 (HER2) (Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-13). detail...
ERBB2 over exp breast cancer sensitive ZW49 Preclinical - Pdx Actionable In a preclinical study, ZW49 treatment induced tumor regression in a patient-derived xenograft (PDX) model of breast cancer overexpressing ERBB2 (HER2) (Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-13). detail...